Amphastar Pharmaceuticals (AMPH) Non-Current Assets (2013 - 2026)

Amphastar Pharmaceuticals' Non-Current Assets history runs 14 years deep, the most recent figure standing at $1.0 billion for Q1 2026.

• On a quarterly basis, Non-Current Assets fell 2.3% year-over-year to $1.0 billion in Q1 2026; TTM through Mar 2026 was $4.1 billion, a 0.51% decrease from a year earlier, with the FY2025 full-year figure at $993.3 million, down 4.8% from the prior year.
• Non-Current Assets improved to $1.0 billion in Q1 2026 per AMPH's latest filing, from $993.3 million in the prior quarter.
• Across five years, Non-Current Assets topped out at $1.0 billion in Q4 2024 and bottomed at $342.5 million in Q3 2022.
• The 5-year median for Non-Current Assets is $1.0 billion (2023), against an average of $821.6 million.
• Across the five-year window, Non-Current Assets jumped 192.47% in 2023 and retreated 4.8% in 2025, its largest moves.
• Year by year, Non-Current Assets stood at $363.7 million in 2022, then surged by 181.39% to $1.0 billion in 2023, then climbed by 1.96% to $1.0 billion in 2024, then slipped by 4.8% to $993.3 million in 2025, then grew by 2.13% to $1.0 billion in 2026.
• Per Business Quant, the three latest AMPH Non-Current Assets figures stand at $1.0 billion (Q1 2026), $993.3 million (Q4 2025), and $1.0 billion (Q3 2025).